https://www.selleckchem.com/products/rxc004.html
Intrinsic malignant brain tumors, such as glioblastomas are frequently resistant to immune checkpoint blockade (IC with few hypermutated glioblastomas showing response. Modeling patient-individual resistance is challenging due to the lack of predictive biomarkers and limited accessibility of tissue for serial biopsies. Here, we investigate resistance mechanisms to anti-PD-1 and anti-CTLA-4 therapy in syngeneic hypermutated experimental gliomas and show a clear dichotomy and acquired immune heterogeneity in ICB-responder and non-respond
Like
Comment
Share
